15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Lexicon Pharmaceuticals Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $3.10 to $6.00, a moderate spread. The average target of $4.55 sits 105% above the current $2.22. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Lexicon Pharmaceuticals Inc.
As of Sep, 2 of 2 firms rate LXRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LXRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.04 – $-0.03 · 3 analysts · -10% YoY
Next period, 3 analysts expect Lexicon Pharmaceuticals Inc to earn $-0.04 a share (range $-0.04 – $-0.03), versus $-0.04 a year earlier. Full-year consensus is $-0.17, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$13.3M
Range $10.0M – $21.7M · 3 analysts · +142% YoY
Revenue is expected to reach $13.3M (range $10.0M – $21.7M), +142.3% year-over-year. Full-year consensus is $37.9M, rising to $19.9M next year.
Top analysts covering Lexicon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LXRX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$6.00+170.3% to target
Overall win rate
33%
+ Follow
#2
Joseph Stringer
Needham · Rank #195
Hold
No targeton LXRX
Overall win rate
36%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$3.10+39.6% to target
Overall win rate
41%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$6.00+170.3% to target
Overall win rate
34%
+ Follow
#5
Roanna Ruiz
SVB Leerink · Rank #388
Hold
$1.00-55.0% to target
Overall win rate
31%
+ Follow
LXRX stock forecast FAQ
What is LXRX's average 12-month price target?+
The 2 analysts with a live target average $4.55 for Lexicon Pharmaceuticals Inc over the next 12 months, ranging from a $6.00 high to a $3.10 low.
Is LXRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LXRX?+
The Street-high target is $6.00 (HC Wainwright & Co.), and the Street-low is $3.10 (Citigroup). The average of all 2 active targets is $4.55.
How many Wall Street analysts cover LXRX?+
2 analysts have an active rating on Lexicon Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering LXRX?+
Among analysts who currently cover LXRX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #188). Their current call is Buy with a $6.00 target.
What is Lexicon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.04 – $-0.03) across 3 analysts. Full-year EPS is projected at $-0.17, rising to $-0.19 the following year.
How much revenue is Lexicon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $13.3M (range $10.0M – $21.7M). Full-year revenue is projected at $37.9M, growing to $19.9M next year.
Have analysts been upgrading or downgrading LXRX lately?+
As of Sep, 2 of 2 firms rate LXRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LXRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
